KLRS

$3.94+$0.06 (+1.55%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$93.8M

24M shares

52-week range

$2.14 – $11.88

18% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change$-7.53

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-2.06	$-2.26–$-1.67	—	6
2027	$10M	—	$-1.63	$-1.79–$-1.41	—	6
2028	$0	-100.0%	$-2.28	$-3.71–$-1.28	—	5
2029	$4M	—	$-2.56	$-2.56–$-2.56	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 5 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-11	$-0.49	$-0.48	+3.0%
2026-05-12	$-0.52	$-0.46	+11.5%
2026-03-17	$-0.56	$-0.44	+21.4%
2025-11-12	$-0.66	$-0.64	+3.0%
2025-08-13	$-0.51	$-0.61	-19.6%
2025-05-14	$-0.78	$-2.52	-223.1%
2025-03-07	$-2.76	$-3.64	-31.8%
2024-11-12	$-0.14

DCF fair valuemodel estimate

Intrinsic value

$6.25

Price

$3.94

Implied upside

+59%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
KLRSKalaris Therapeutics Inc	$4.00	+3.22%	$87M	—
ARTVArtiva Biotherapeutics, Inc.	$10.96	-3.05%	$536M	—
CNTBConnect Biopharma Holdings Limited	$2.42	-4.72%	$152M	—
CNTXContext Therapeutics Inc.	$0.51	+0.26%	$47M	—
IFRXInflaRx N.V.	$1.93	-3.98%

Kalaris Therapeutics, Inc. Common Stock

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

www.kalaristx.com

Employees: 20
IPO / List date: Mar 19, 2025
HQ: BERKELEY HEIGHTS, NJ

Held by traders on TradeandTell

No one on the platform currently holds KLRS.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	66,151	$381.7K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded KLRS yet.

$KLRS chatter on StockTwits

pedro@BiotechButterfliesAug 3
$KLRS still nibbling here... plenty time... good opp
View on StockTwits ↗
Dixie@dixiebullJul 20
$ADVB $CCXI $FIG $KLRS ADVB thank ya
View on StockTwits ↗
Top Stock Alerts@topstockalertsJul 20
Kalaris Therapeutics announced the appointment of Liisa Bayko as its new Chief Financial Officer. Bayko brings more than 20 years of biotechnology finance experience, most recently serving as Managing Director and Senior Biotechnology Analyst at Evercore ISI, where she covered small- and mid-cap biotech companies. Her background also includes senior roles at JMP Securities, Next Generation Equity Research, Prudential Equity Group, and Baker Brothers Advisors. The appointment comes as Kalaris continues patient enrollment in its Phase 1b/2 trial evaluating TH103 for treatment-naïve patients with neovascular age-related macular degeneration. TH103 is an investigational dual-target biologic designed for intravitreal administration with potential applications across multiple retinal diseases, including wet AMD, diabetic eye disease, and retinal vein occlusion. Management highlighted Bayko's expertise in biotech valuation. $KLRS
View on StockTwits ↗
Dixie@dixiebullJul 20
$ADVB $CCXI $FIG $KLRS ADVB halter
View on StockTwits ↗
Dixie@dixiebullJul 20
$ADVB $CCXI $FIG $KLRS KLRS did hold 4 but has that 200ma res
View on StockTwits ↗
DonnyDee@DonnyDeeJul 20
$ADVB $CCXI $FIG $KLRS
View on StockTwits ↗
Dixie@dixiebullJul 20
$ADVB $CCXI $FIG $KLRS ADVB let's go 10
View on StockTwits ↗
Dixie@dixiebullJul 19
$ADVB risky but if 6.50 breaks it can run to 8 and 10 $CCXI ran to 15.45 so I am looking for a dip to 14 for a move to 15 break and 15.50 $FIG strong move to 24.39, so 24 break can get 25 to 25.50 $KLRS see if 4 holds for a move to 4.50 and 5 maybe 5.50
View on StockTwits ↗
Merlintrader Trading Pub@MerlintraderJul 19
$FDMT ASRS 2026 Retina Showdown: New Data Put $FDMT, $RGNX and $KLRS Under the Spotlight https://www.merlintrader.com/asrs-2026-retina-showdown/
View on StockTwits ↗
Oscarthesuperstar1@Oscarthesuperstar1BullishJul 18
$KLRS I believe it’s a hold. Price targets up to $25.
View on StockTwits ↗
HellenicRenegade@HellenicRenegadeJul 17
$KLRS Gonna hit $12 in PH 😂
View on StockTwits ↗
HellenicRenegade@HellenicRenegadeJul 17
$KLRS Funny how this board went dead silent 🤫
View on StockTwits ↗
Jay Gunn@paid2winBearishJul 17
$KLRS No support below $5.08
View on StockTwits ↗
Jay Gunn@paid2winBearishJul 17
$KLRS You knew it was only a Phase 1 Study. Volume will disappear on Monday when it settles back into mediocrity.
View on StockTwits ↗
Top Stock Alerts@topstockalertsJul 17
$KLRS this has “underestimated” written all over it.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.